Drug Alerts & Adverse Event Reporting
Xultophy 100/3.6 is a combination insulin indicated for adults with Type 2 Diabetes Mellitus. It is associated with an increased risk of acute pancreatitis and a potential risk of medullary thyroid carcinoma. Clinicians should refer to the Xultophy 100/3.6 REMS(51 KB PDF) when prescribing this medication (link).
Receive Drug Alerts
The AAFP has partnered with PDR Drug Alerts(www.pdr.net) to help you receive FDA-mandated and product-related patient safety alerts as soon as they are issued.
Features of PDR Drug Alerts include:
- Ability to appoint a family medicine team member to manage practice alerts
- Free for U.S.-based prescribers
- Traditional "dear doctor letter" (DDL) sent when online alert has not been reviewed within 72 hours (weekends not included)
- Email addresses kept secure and confidential
- Access to 12-month alert history master file
- No advertisements
- Information paid for by manufacturers required by the FDA to deliver safety alerts
- Exclusive specialty-specific service fulfilling FDA guidance for electronic delivery of drug warnings
Get PDR Drug Alerts
Receive urgent FDA-mandated and product-related patient-safety alerts from PDR Drug Alerts.
Adverse Event Reporting
Using RxEvent, U.S. physicians and other health care providers can easily and effectively report adverse drug events. This service is a collaboration of medical professional insurance carriers and governmental experts.
Features of RxEvent include:
- Easy-to-use, standardized report form with pre-populated information
- Minimal required questions
- Prompt acknowledgment sent upon submission of a report
RxEvent has been established for use by U.S. health care professionals for reporting adverse events on U.S.-distributed drugs only.
ADVERSE DRUG EVENTS REPORTING
U.S. health care professionals may report adverse events on U.S.-distributed drugs only.